search
Back to results

Collaborative Research Group for Necrotizing Enterocolitis

Primary Purpose

Prematurity, Necrotizing Enterocolitis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
[5,5,5-2H3]leucine (stable isotope labeled leucine)
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Prematurity focused on measuring newborn, necrotizing enterocolitis, genetics, growth factors, metabolism

Eligibility Criteria

1 Day - 7 Days (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • gestation 32 weeks or less
  • 1 week of age or less
  • intravenous line in place for clinical purposes

Exclusion Criteria:

  • imminent death
  • active infection
  • pre-existing diagnosis of NEC
  • fluid or electrolyte imbalance

Sites / Locations

  • St. Louis Children's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Preterm Infants for EGF Profiles

Arm Description

Premature infants born at < 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of [5,5,5-2H3]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.

Outcomes

Primary Outcome Measures

Salivary EGF (Epidermal Growth Factor) Protein Levels
Salivary EGF protein levels obtained from oral swabs were analyzed by commercially available EGF ELISA kit (R &D systems Inc). EGF protein levels were normalized to micrograms of protein in saliva, and expressed as picogram of EGF protein per microgram of total salivary protein.
Urinary EGF Protein Levels
Urinary EGF protein levels obtained from free flowing urine samples retrieved from subject diaper were analyzed by commercially available EGF ELISA kit (R &D systems Inc). EGF protein levels were normalized to milligrams of creatinine in urine, and expressed as nanograms of EGF protein per milligram of urinary creatinine.

Secondary Outcome Measures

EGF Gene Sequencing
Identification of computationally predicted functional variants in EGF gene

Full Information

First Posted
January 22, 2009
Last Updated
March 7, 2018
Sponsor
Washington University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT00828451
Brief Title
Collaborative Research Group for Necrotizing Enterocolitis
Official Title
Collaborative Research Group for Necrotizing Enterocolitis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
May 2008 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This proposal will test the hypothesis that synthesis and catabolism of epidermal growth factor (EGF), the genotype of the EGF gene, and the microbiome interact to influence EGF expression in infants at risk for necrotizing enterocolitis (NEC).
Detailed Description
Preterm infants will receive a six hour intravenous infusion of [5,5,5-2H3]leucine (2H3) through an existing intravenous line (IV) to measure EGF synthesis rate. Two blood samples will be obtained, one prior to the start of infusion, and one during the infusion. The enrichment of the stable isotope labeled leucine will be measured in the plasma from these samples; DNA will be extracted from the residual cell pellets. The EGF and EGF receptor genes will be sequenced. Saliva and urine will be obtained for 5 days following infusion to measure EGF and the rate of incorporation of leucine into EGF using liquid chromatography (LC)/mass spectroscopy (MS)/MS technology, as well as enzyme-linked immunosorbent assay (ELISA) . Saliva will be obtained by a Q tip swab and urine and stool obtained from the diaper. Stool will be obtained every 3 to 7 days through 5 weeks to evaluate inflammatory markers and the microbiome. If breastfeeding, a single sample of mother's milk will be obtained for measurement of EGF after adequate volumes for infant feeds are achieved.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prematurity, Necrotizing Enterocolitis
Keywords
newborn, necrotizing enterocolitis, genetics, growth factors, metabolism

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
29 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Preterm Infants for EGF Profiles
Arm Type
Experimental
Arm Description
Premature infants born at < 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of [5,5,5-2H3]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.
Intervention Type
Biological
Intervention Name(s)
[5,5,5-2H3]leucine (stable isotope labeled leucine)
Intervention Description
intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
Primary Outcome Measure Information:
Title
Salivary EGF (Epidermal Growth Factor) Protein Levels
Description
Salivary EGF protein levels obtained from oral swabs were analyzed by commercially available EGF ELISA kit (R &D systems Inc). EGF protein levels were normalized to micrograms of protein in saliva, and expressed as picogram of EGF protein per microgram of total salivary protein.
Time Frame
Sampling occurred on average day of life 9 with a range from day of life 7 to 21
Title
Urinary EGF Protein Levels
Description
Urinary EGF protein levels obtained from free flowing urine samples retrieved from subject diaper were analyzed by commercially available EGF ELISA kit (R &D systems Inc). EGF protein levels were normalized to milligrams of creatinine in urine, and expressed as nanograms of EGF protein per milligram of urinary creatinine.
Time Frame
Sampling occurred on average day of life 9 with a range from day of life 7 to 21
Secondary Outcome Measure Information:
Title
EGF Gene Sequencing
Description
Identification of computationally predicted functional variants in EGF gene
Time Frame
Sampling occurred on average day of life 9 with a range from day of life 7 to 21

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
7 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: gestation 32 weeks or less 1 week of age or less intravenous line in place for clinical purposes Exclusion Criteria: imminent death active infection pre-existing diagnosis of NEC fluid or electrolyte imbalance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aaron Hamvas, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Louis Children's Hospital
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
18346534
Citation
Nair RR, Warner BB, Warner BW. Role of epidermal growth factor and other growth factors in the prevention of necrotizing enterocolitis. Semin Perinatol. 2008 Apr;32(2):107-13. doi: 10.1053/j.semperi.2008.01.007.
Results Reference
background
PubMed Identifier
17382110
Citation
Warner BB, Ryan AL, Seeger K, Leonard AC, Erwin CR, Warner BW. Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis. J Pediatr. 2007 Apr;150(4):358-63. doi: 10.1016/j.jpeds.2006.11.059.
Results Reference
background
PubMed Identifier
16227034
Citation
Spence KL, Zozobrado JC, Patterson BW, Hamvas A. Substrate utilization and kinetics of surfactant metabolism in evolving bronchopulmonary dysplasia. J Pediatr. 2005 Oct;147(4):480-5. doi: 10.1016/j.jpeds.2005.04.039.
Results Reference
background
PubMed Identifier
15772427
Citation
Bohlin K, Patterson BW, Spence KL, Merchak A, Zozobrado JC, Zimmermann LJ, Carnielli VP, Hamvas A. Metabolic kinetics of pulmonary surfactant in newborn infants using endogenous stable isotope techniques. J Lipid Res. 2005 Jun;46(6):1257-65. doi: 10.1194/jlr.M400481-JLR200. Epub 2005 Mar 16.
Results Reference
background

Learn more about this trial

Collaborative Research Group for Necrotizing Enterocolitis

We'll reach out to this number within 24 hrs